Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STI-6129 in Relapsed or Refractory Multiple Myeloma
NCT05565807Phase 2Recruiting
- Sponsor
- ACEA Pharmaceuticals
- Start
- Feb 2023
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of STI-6129 in multiple myeloma (MM), sponsored by ACEA Pharmaceuticals. Started Feb 2023; status: recruiting.
02
Drugs
STI-6129
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05565807.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05565807.